Dr. Sonia Anand, Professor of Medicine and a vascular medicine specialist at McMaster University, explains the pathophysiology of atherothrombosis and discusses the findings from pivotal clinical trials like COMPASS and Voyager, which explore the efficacy of combining novel oral anticoagulants (NOACs) with antiplatelet agents in treating PAD.

Key Highlights:

Pathophysiology of Atherothrombosis: An indepth look at the various pathways involved in blood clot formation within the arteries and the role of new therapies like Factor 10A Inhibitors.
COMPASS and Voyager Trials: Detailed discussion of these critical trials, which examined the effectiveness of dual pathway inhibition (lowdose rivaroxaban plus aspirin) in PAD patients.
Reduced Risk of Major Adverse Cardiovascular Events (MACE): Highlighting the significant reduction in MACE and Major Adverse Limb Events (MALE) with dual pathway inhibition compared to aspirin alone.
Bleeding Risks Analysis: Assessing the impact of intensified antithrombotic therapies on major and severe bleeding risks.
Suitability of Dual Pathway Inhibition: Understanding which patients are best suited for this treatment strategy, balancing benefits against bleeding risks.

Who Should Watch:

Vascular medicine specialists, cardiologists, and healthcare providers treating patients with PAD.
Medical researchers and students interested in the latest developments in cardiovascular disease treatments.
Patients and caregivers looking for comprehensive information on PAD management and treatment options.

Stay Connected:

Follow us for more expert insights: twitter.com/vascularcures
Explore extensive resources on PAD: vascularcures.org
Engage with Us:

Join the conversation in the comments section below.
Subscribe to our channel for more informative sessions on vascular health.

#DualPathwayInhibition #PeripheralArteryDisease #Atherothrombosis #VascularMedicine #COMPASSTrial #VoyagerTrial #HealthcareEducation #McMasterUniversity